C. Barrière

发表

Cdk1 is sufficient to drive the mammalian cell cycle

Pierre Dubus, M. Barbacid, M. Malumbres, 2007, Nature.

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Shanghai Yu, Liu Liu, Wei Sun, 2014, Cancer research.

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

D. Wiederschain, S. Guérif, V. Blanc, 2021, Oncoimmunology.

Mice thrive without Cdk4 and Cdk2

M. Barbacid, M. Malumbres, Alberto Martin, 2007, Molecular oncology.

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma

C. Creighton, A. Lazar, R. Pollock, 2015, Clinical Cancer Research.

Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut

Inna Kuperstein, Emmanuel Barillot, Loredana Martignetti, 2014, Nature Communications.

Abstract 4648: In vitro characterization of spiro-oxindole-based modulators of the MDM2-p53 interaction and their interspecies selectivity.

Shaomeng Wang, J. Watters, C. García-echeverría, 2012 .

Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors.

M. Mathieu, C. García-echeverría, F. Gay, 2014, Journal of medicinal chemistry.

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Aaron J. Johnson, J. Sarkaria, J. Watters, 2018, Molecular Cancer Therapeutics.

Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma

C. Creighton, A. Lazar, R. Pollock, 2022, Clinical Cancer Research.